<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261335</url>
  </required_header>
  <id_info>
    <org_study_id>CAMCR-014</org_study_id>
    <secondary_id>jRCT2043190112</secondary_id>
    <nct_id>NCT04261335</nct_id>
  </id_info>
  <brief_title>The Clinical Trial of CL2020 Cells for Neonatal Hypoxic Ischemic Encephalopathy</brief_title>
  <acronym>SHIELD</acronym>
  <official_title>The Evaluation of Safety and Tolerability of CL2020 in Neonatal Hypoxic Ischemic Encephalopathy Patients With Therapeutic Hypothermia in the Dose Escalation Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nagoya University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Life Science Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nagoya University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and the tolerability of CL2020 cells in
      hypoxic ischemic encephalopathy neonates with hypothermia therapy. In addition, we will
      evaluate the efficacy of CL2020 cells for infant development.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>3 + 3 dose escalation study design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>until 12 weeks after the administration</time_frame>
    <description>Any adverse events are summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of composite endpoints (death, continuous respiratory support, and continuous use of vasopressors or pulmonary vasodilators)</measure>
    <time_frame>at 12, 26, 38, 52, and 78 weeks after administration</time_frame>
    <description>Incidence of composite endpoints is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>all of the clinical trial period (up to 44 months)</time_frame>
    <description>Mortality is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>all of the clinical trial period (up to 44 months)</time_frame>
    <description>Overall survival is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of continuous respiratory support</measure>
    <time_frame>up to 78 weeks</time_frame>
    <description>Duration of continuous respiratory support is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of continuous use of vasopressors or pulmonary vasodilators</measure>
    <time_frame>up to 78 weeks</time_frame>
    <description>Duration of continuous use of vasopressors or pulmonary vasodilators is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite score of cognitive scale, language scale, motor scale, social-emotional scale, and adaptive behavior scale in Bayley Scales of Infant and Toddler Development Third edition</measure>
    <time_frame>78 weeks after administration</time_frame>
    <description>Each composite scores are summarized. The higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The developmental quotient in Kyoto Scale of Psychological Development 2001</measure>
    <time_frame>78 weeks after administration</time_frame>
    <description>The developmental quotient is summarized. The higher scores mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of 1) head control, 2) roll over, 3) sitting position, 4) crawl, 5) independent gait, and 6) meaningful words</measure>
    <time_frame>at 26, 38, 52, and 78weeks after administration</time_frame>
    <description>Presence of each event is summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of spasticity</measure>
    <time_frame>at 12, 26, 38, 52, and 78 weeks after administration</time_frame>
    <description>Presence of spasticity is summarized. Spasticity is the condition as below: increased muscle tone, or increased deep tendon reflex.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of epilepsy</measure>
    <time_frame>until 78 weeks after administration</time_frame>
    <description>Presence of spasticity is summarized. The definition of epilepsy is the condition based on the International League Against Epilepsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI score</measure>
    <time_frame>at 2, and 78 weeks after administration</time_frame>
    <description>MRI score is summarized. The scoring system is based on the report of Barkovich AJ, et al. (AJNR Am J Neuroradiol. 1998 ;19(1):143-9.) . The higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gross Motor Function Classification System (GMFCS) score</measure>
    <time_frame>at 78 weeks after administration</time_frame>
    <description>GMFCS score is summarized. The gross motor function can be categorized into 5 different level. The higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hypoxia-Ischemia, Brain</condition>
  <arm_group>
    <arm_group_label>CL2020 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous injection of CL2020 cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CL2020 cells</intervention_name>
    <description>1.5 million or 15 million cells, IV on day 5 to 14 of birth</description>
    <arm_group_label>CL2020 cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 36 weeks gestation, and either one of the following criteria (i.-iii.) i.
             Apgar score ≤5 at 10 minutes ii. Continued resuscitation for at least 10 minutes iii.
             pH &lt;7.0 or base deficit ≥16 mmol/L in any blood sample obtained within 60 min of birth

          2. Moderate or severe encephalopathy by a Sarnat criteria

          3. Undergone therapeutic hypothermia started before six hours of birth, and done for 72
             hours continuously

          4. Birth weight ≥1,800 g

          5. Heart rate ≥100/min, and SpO2 ≥90 %

          6. Able to provide voluntary written consent after receiving adequate information about
             the study (consent will be obtained from an acceptable representative)

        Exclusion Criteria:

          1. Suspected or confirmed severe congenital abnormalities or chromosomal anomaly

          2. Planned to undergo surgery or radiation therapy

          3. Scheduled to take systemic corticosteroids treatment for over five days

          4. Blood glucose ≥ 200 mg/dL

          5. Participation in another clinical study (not exclude patients in observational
             studies)

          6. Suspected or confirmed active and severe infection

          7. Positive for HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody or syphilis
             serum reaction

          8. History of severe hypersensitivity or anaphylactic reaction

          9. Severe complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshiaki Sato, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Center for Maternal Neonatal Care, Nagoya University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoshiaki Sato, MD, PhD</last_name>
    <phone>+81-52-741-2985</phone>
    <email>yoshiaki@med.nagoya-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kazuto Ueda, MD</last_name>
    <phone>+81-52-744-2985</phone>
    <email>ueda.kazuto@med.nagoya-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aich</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshiaki Sato, MD, Ph.D</last_name>
      <phone>+81-52-741-2985</phone>
      <email>yoshiaki@med.nagoya-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 1, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nagoya University</investigator_affiliation>
    <investigator_full_name>Yoshiaki Sato</investigator_full_name>
    <investigator_title>MD, PhD, Associate Professor at Department of Center for Maternal Neonatal Care, Nagoya University Hospital</investigator_title>
  </responsible_party>
  <keyword>Hypoxia-Ischemia, Brain</keyword>
  <keyword>Infant, Newborn</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

